The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 32 | — | 20.1x | Below average | |
Growth | 35 | -52.6% | 5.6% | Near average | |
Quality | 10 | -62.9% | 7.6% | Below average | |
Safety | 26 | 1.4x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Fate Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Fate Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Fate Therapeutics stock shows a state of complete stability in price targets at $4, with zero Analyst Dispersion as the high, low, and mean values coincide. The most notable observation is the addition of a new analyst over the last 30 days, bringing the total count to 3 analysts, while adopting the same previous price target. This reinforces the collective conviction at this price level despite the significant gap from the current price ($2.25).
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.